Has Mohammad Janjua, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,913 in general payments to Mohammad Janjua, MD across 284 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mohammad Janjua, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mohammad Janjua, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mohammad Janjua, MD

Psychiatry · Reading, PANPI 1740268317

Payments from drug & device makers

$5,913in general payments, 2019–2025

Across 284 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$967
Otsuka America Pharmaceutical, Inc.$645
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$540
Sunovion Pharmaceuticals Inc.$535
Johnson & Johnson$533
Alkermes, Inc.$427
plus $2K from 26 others

What the payments were for

Food & beverage$5,85099%
Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	44	$967
Otsuka America Pharmaceutical, Inc.	32	$645
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	29	$540
Sunovion Pharmaceuticals Inc.	29	$535
Johnson & Johnson	23	$533
Alkermes, Inc.	29	$427
Lundbeck LLC	18	$361
Takeda Pharmaceuticals U.S.A., Inc.	14	$294
Bausch Health US, LLC	5	$204
Medtronic	1	$161
Supernus Pharmaceuticals, Inc.	8	$152
Vanda Pharmaceuticals Inc.	5	$144
Portola Pharmaceuticals, LLC	1	$119
AbbVie	5	$113
E.r. Squibb & Sons, L.L.C.	5	$96
Merck	6	$92
Ironshore Pharmaceuticals Inc.	3	$61
Noven Therapeutics, LLC	3	$55
Axsome Therapeutics, Inc.	3	$52
Almatica Pharma LLC	2	$49
Shire North American Group Inc	3	$39
Tris Pharma Inc	2	$39
Idorsia Pharmaceuticals US Inc	2	$34
Teva Pharmaceuticals USA, Inc.	2	$32
Indivior Inc.	2	$32
Avanir Pharmaceuticals, Inc.	2	$31
Avion Pharmaceuticals	1	$28
Eisai Inc.	1	$24
Adlon Therapeutics L.p.	1	$16
Biogen	1	$14
Jazz Pharmaceuticals Inc.	1	$12
Vertical Pharmaceuticals, LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,913 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$63,603

Medicare patients

Services billed

755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LatudaLurasidone Hcl	65	$94,844
Invega SustennaPaliperidone Palmitate	11	$17,846
Aripiprazole	259	$14,728
Lurasidone Hcl	42	$14,693
ZoloftSertraline Hcl	13	$11,305
VyvanseLisdexamfetamine Dimesylate	20	$7,667
Quetiapine Fumarate ErQuetiapine Fumarate	44	$6,655
TrintellixVortioxetine Hydrobromide	13	$6,260
Asenapine Maleate	39	$5,849
Trazodone Hcl	991	$5,806
Bupropion Hcl SrBupropion Hcl	318	$5,551
Atomoxetine Hcl	96	$5,458
Quetiapine Fumarate	467	$5,138
Sertraline Hcl	748	$4,987
Paliperidone ErPaliperidone	17	$4,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Sunovion Pharmaceuticals Inc.Latuda	$535	$94,84465 claims
Johnson & JohnsonInvega Sustenna	$533	$17,84611 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix	$294	$13,92733 claims
Almatica Pharma LLCSertraline Hcl	$49	$4,987748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.